Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
Article Abstract:
Methotrexate therapy for rheumatoid arthritis may increase blood levels of homocysteine, a possible risk factor for coronary artery disease. Researchers compared 105 patients treated with sulphasalazine, methotrexate, or a combination of the drugs for rheumatoid arthritis. Sulphasalazine alone caused only a small and temporary increase in homocysteine levels. Methotrexate alone caused a persistent rise in homocysteine, and the drug combination caused a marked increase in homocysteine levels in the blood. A variant of a gene which controls production of an enzyme, present in 10 patients, was likely responsible for the effect of the antirheumatic drugs on homocysteine levels.
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Methotrexate treatment in patients with adult onset Still's disease - retrospective of 13 Japanese cases
Article Abstract:
Methotrexate may successfully treat patients with adult onset Still's disease (AOSD); however side effects may be common and severe. Of 13 patients with symptomatic AOSD, methotrexate treatment relieved symptoms and improved laboratory values in 8 patients within 16 weeks of beginning treatment. Other medications could be reduced or discontinued. Four patients did not respond. One patient discontinued treatment because of severe nausea. Five patients experienced adverse effects, including acute interstitial pneumonia and liver toxicity. Five of the eight successfully treated patients were HLA-DR4 positive whereas all unsuccessfully treated patients were DR2 positive.
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate
Article Abstract:
Methotrexate treatment for rheumatoid arthritis does not appear to predispose patients to developing cancer. Researchers compared cancer incidence rates among 426 rheumatoid arthritis patients treated for an average of 37 months with methotrexate, 420 similar patients not treated with methotrexate, and more than 800,000 people living in the area. The average length of follow-up was 4 1/2 years. Patients treated with methotrexate were not more likely to develop cancer compared with rheumatoid arthritis patients not so treated. Neither group was statistically more likely to develop cancer than the background population; however, the follow-up period was short.
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Antibody deficiency associated with gold treatment: natural history and management in 22 patients
- Abstracts: Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis
- Abstracts: The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists
- Abstracts: Neuropathology of the brainstem and spinal cord in end stage rheumatoid arthritis: implications for treatment
- Abstracts: It's not just for breakfast anymore; vitamin C - and a cabinet full of other nutrients - is the latest tool in the war on wrinkles